{"pmid":32349579,"pmcid":"PMC7202359","title":"COVID-19: the use of immunotherapy in metastatic lung cancer.","text":["COVID-19: the use of immunotherapy in metastatic lung cancer.","Immunotherapy","Davis, Alexander P","Boyer, Michael","Lee, Jenny H","Kao, Steven C","32349579"],"journal":"Immunotherapy","authors":["Davis, Alexander P","Boyer, Michael","Lee, Jenny H","Kao, Steven C"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32349579","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.2217/imt-2020-0096","keywords":["covid-19","duration of therapy","immune checkpoint inhibitors","immunotherapy","lung cancer"],"topics":["Prevention"],"weight":1,"_version_":1666138495656132610,"score":9.490897,"similar":[{"pmid":32468851,"title":"Facing SARS-CoV-2 outbreak in immunotherapy era.","text":["Facing SARS-CoV-2 outbreak in immunotherapy era.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread represents a sanitary emergency all over the world. Viral biology is only partially known with some aspects in common with other CoV and the damage observed in most severe cases is due to intense inflammation. Immunotherapy restores immunological activity against cancer cells and it has become a standard treatment for several cancers. We carried out an examination of available data concerning with the effects exerted by both SARS-CoV-2 and the most widespread immunotherapy treatments on the immune system in order to hypothesize mechanisms underlying potential and mutual interaction. We provided an analysis of laboratory, clinical and therapeutic data related with severe acute respiratory syndrome coronavirus. We finally focused on implications of immunotherapy treatments in clinical practice.","Future Oncol","Citarella, Fabrizio","Russano, Marco","Pantano, Francesco","Dell'Aquila, Emanuela","Vincenzi, Bruno","Tonini, Giuseppe","Santini, Daniele","32468851"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread represents a sanitary emergency all over the world. Viral biology is only partially known with some aspects in common with other CoV and the damage observed in most severe cases is due to intense inflammation. Immunotherapy restores immunological activity against cancer cells and it has become a standard treatment for several cancers. We carried out an examination of available data concerning with the effects exerted by both SARS-CoV-2 and the most widespread immunotherapy treatments on the immune system in order to hypothesize mechanisms underlying potential and mutual interaction. We provided an analysis of laboratory, clinical and therapeutic data related with severe acute respiratory syndrome coronavirus. We finally focused on implications of immunotherapy treatments in clinical practice."],"journal":"Future Oncol","authors":["Citarella, Fabrizio","Russano, Marco","Pantano, Francesco","Dell'Aquila, Emanuela","Vincenzi, Bruno","Tonini, Giuseppe","Santini, Daniele"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468851","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.2217/fon-2020-0340","keywords":["covid-19","sars-cov-2","immune checkpoint inhibitors","immunotherapy","inflammation"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668167109868257280,"score":128.10805},{"pmid":32212881,"pmcid":"PMC7117596","title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","text":["Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","Immunotherapy","Bersanelli, Melissa","32212881"],"journal":"Immunotherapy","authors":["Bersanelli, Melissa"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32212881","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.2217/imt-2020-0067","keywords":[" anti-ctla-4","covid-19","sars-cov-2","anti-pd-1","anti-pd-l1","cancer patients","immune checkpoint inhibitors","immunotherapy","tocilizumab","viral infection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490525450240,"score":94.686615},{"pmid":32489118,"title":"Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors.","text":["Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors.","Immunotherapy","Vici, Patrizia","Pizzuti, Laura","Krasniqi, Eriseld","Botticelli, Andrea","Ciliberto, Gennaro","Barba, Maddalena","32489118"],"journal":"Immunotherapy","authors":["Vici, Patrizia","Pizzuti, Laura","Krasniqi, Eriseld","Botticelli, Andrea","Ciliberto, Gennaro","Barba, Maddalena"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489118","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.2217/imt-2020-0142","keywords":["covid-19","immunotherapy","metastatic triple-negative breast cancer"],"topics":["Prevention"],"weight":1,"_version_":1668623433729048577,"score":77.64769},{"pmid":32272396,"pmcid":"PMC7128194","title":"The possible of immunotherapy for COVID-19: A systematic review.","text":["The possible of immunotherapy for COVID-19: A systematic review.","The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.","Int Immunopharmacol","AminJafari, Akram","Ghasemi, Sorayya","32272396"],"abstract":["The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option."],"journal":"Int Immunopharmacol","authors":["AminJafari, Akram","Ghasemi, Sorayya"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272396","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.intimp.2020.106455","keywords":["2019-ncov","covid-19","immunotherapy","interleukin","monoclonal antibody","vaccine"],"topics":["Treatment"],"weight":1,"_version_":1666138491757527040,"score":74.29612},{"pmid":32323577,"pmcid":"PMC7192200","title":"What the oncologist needs to know about COVID-19 infection in cancer patients.","text":["What the oncologist needs to know about COVID-19 infection in cancer patients.","Future Oncol","Rassy, Elie","Khoury-Abboud, Rita-Maria","Ibrahim, Nathalie","Kattan, Clarisse","Assi, Tarek","Kattan, Joseph","32323577"],"journal":"Future Oncol","authors":["Rassy, Elie","Khoury-Abboud, Rita-Maria","Ibrahim, Nathalie","Kattan, Clarisse","Assi, Tarek","Kattan, Joseph"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32323577","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.2217/fon-2020-0312","keywords":["covid-19","chemotherapy","coronavirus","immune checkpoint inhibitors","oncologist","oncology","review"],"topics":["Prevention"],"weight":1,"_version_":1666138493801201665,"score":68.8514}]}